Azher Hussain

Family Medicine

8116 Good Luck Rd Ste 300
Lanham, MD 20706

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial.

Gefapixant as a P2X3 receptor antagonist treatment for obstructive sleep apnea: a randomized controlled trial.

Journal: Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Published: July 29, 2024

Oncology Combination Drug Development Strategies for Project Optimus.

Oncology Combination Drug Development Strategies for Project Optimus.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 13, 2024

Randomized, controlled, proof-of-concept trial of gefapixant for endometriosis-related pain.

Randomized, controlled, proof-of-concept trial of gefapixant for endometriosis-related pain.

Journal: Fertility and sterility

Published: May 07, 2024

Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper.

Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper.

Journal: Clinical pharmacology and therapeutics

Published: February 09, 2024

Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.

Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.

Journal: Journal of clinical pharmacology

Published: November 20, 2023

Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixant.

Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixant.

Journal: CPT: pharmacometrics & systems pharmacology

Published: April 03, 2023

Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.

Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.

Journal: Journal of clinical pharmacology

Published: March 04, 2022

A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults.

A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults.

Journal: Lung

Published: February 28, 2022

The PET tracer [11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's disease.

The PET tracer [11C]MK-6884 quantifies M4 muscarinic receptor in rhesus monkeys and patients with Alzheimer's disease.

Journal: Science translational medicine

Published: January 12, 2022

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans.

Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans.

Journal: Pharmacology research & perspectives

Published: January 10, 2022

Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough.

Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic Cough.

Journal: Clinical pharmacology in drug development

Published: January 07, 2022

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin.

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin.

Journal: Clinical pharmacology in drug development

Published: June 09, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026